PROM1 and glioma: Next, the self‐renewal and tumorigenic abilities of CD133+ glioma cells expressing CD133 shRNA and either shRNA‐resistant wild‐type CD133 or shRNA‐resistant CD133(1–862) mutant were evaluated.